CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer
Authors
Smith, Danielle JLunj, Sapna
Adamson, A. D.
Nagarajan, S.
Smith, T. A. D.
Reeves, K. J.
Hoskin, Peter J
Choudhury, Ananya
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
Gene editing technologies help identify the genetic perturbations driving tumour initiation, growth, metastasis and resistance to therapeutics. This wealth of information highlights tumour complexity and is driving cancer research towards precision medicine approaches based on an individual's tumour genetics. Bladder cancer is the 11th most common cancer in the UK, with high rates of relapse and low survival rates in patients with muscle-invasive bladder cancer (MIBC). MIBC is highly heterogeneous and encompasses multiple molecular subtypes, each with different responses to therapeutics. This evidence highlights the need to identify innovative therapeutic targets to address the challenges posed by this heterogeneity. CRISPR-Cas9 technologies have been used to advance our understanding of MIBC and determine novel drug targets through the identification of drug resistance mechanisms, targetable cell-cycle regulators, and novel tumour suppressor and oncogenes. However, the use of these technologies in the clinic remains a substantial challenge and will require careful consideration of dosage, safety and ethics. CRISPR-Cas9 offers considerable potential for revolutionizing bladder cancer therapies, but substantial research is required for validation before these technologies can be used in the clinical setting. In this Perspective, the authors provide an overview of current research using CRISPR-Cas gene editing technologies to understand biological mechanisms and identify novel therapeutic targets in muscle-invasive bladder cancer. Future perspectives about the use of CRISPR-based therapeutics in the clinic, as well as current limitations and ethical considerations, are also discussed.Citation
Smith DJ, Lunj S, Adamson AD, Nagarajan S, Smith TAD, Reeves KJ, et al. CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer. NATURE REVIEWS UROLOGY. 2024 2024 JUL 1. PubMed PMID: WOS:001259388700001. English.Journal
Nature Reviews UrologyDOI
10.1016/j.eclinm.2024.102695PubMed ID
38951705Additional Links
https://dx.doi.org/10.1016/j.eclinm.2024.102695Language
enae974a485f413a2113503eed53cd6c53
10.1016/j.eclinm.2024.102695